The University of Chicago Header Logo

Connection

David A. Ehrmann to Adolescent

This is a "connection" page, showing publications David A. Ehrmann has written about Adolescent.
Connection Strength

0.323
  1. Antimüllerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries. Fertil Steril. 2012 Jul; 98(1):242-9.
    View in: PubMed
    Score: 0.040
  2. Androgens and mood dysfunction in women: comparison of women with polycystic ovarian syndrome to healthy controls. Psychosom Med. 2004 May-Jun; 66(3):356-62.
    View in: PubMed
    Score: 0.023
  3. Effect of Medical and Surgical Interventions on a-Cell Function in Dysglycemic Youth and Adults in the RISE Study. Diabetes Care. 2021 09; 44(9):1948-1960.
    View in: PubMed
    Score: 0.019
  4. Hyperglucagonemia Does Not Explain the ß-Cell Hyperresponsiveness and Insulin Resistance in Dysglycemic Youth Compared With Adults: Lessons From the RISE Study. Diabetes Care. 2021 09; 44(9):1961-1969.
    View in: PubMed
    Score: 0.019
  5. Baseline Predictors of Glycemic Worsening in Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study. Diabetes Care. 2021 09; 44(9):1938-1947.
    View in: PubMed
    Score: 0.019
  6. Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives. J Clin Endocrinol Metab. 2001 May; 86(5):2027-31.
    View in: PubMed
    Score: 0.019
  7. Withdrawal of medications leads to worsening of OGTT parameters in youth with impaired glucose tolerance or recently-diagnosed type 2 diabetes. Pediatr Diabetes. 2020 12; 21(8):1437-1446.
    View in: PubMed
    Score: 0.018
  8. The association of sleep disturbances with glycemia and obesity in youth at risk for or with recently diagnosed type 2 diabetes. Pediatr Diabetes. 2019 12; 20(8):1056-1063.
    View in: PubMed
    Score: 0.017
  9. How to assess diabetes distress: comparison of the Problem Areas in Diabetes Scale (PAID) and the Diabetes Distress Scale (DDS). Diabet Med. 2016 06; 33(6):835-43.
    View in: PubMed
    Score: 0.013
  10. Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations. Nat Commun. 2015 Aug 18; 6:7502.
    View in: PubMed
    Score: 0.013
  11. Adolescent polycystic ovary syndrome due to functional ovarian hyperandrogenism persists into adulthood. J Clin Endocrinol Metab. 2015 Apr; 100(4):1537-43.
    View in: PubMed
    Score: 0.012
  12. Studies of the nature of 17-hydroxyprogesterone hyperresonsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism. J Clin Endocrinol Metab. 1994 Dec; 79(6):1686-92.
    View in: PubMed
    Score: 0.012
  13. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013 Dec; 98(12):4565-92.
    View in: PubMed
    Score: 0.011
  14. Impaired insulin signaling in human adipocytes after experimental sleep restriction: a randomized, crossover study. Ann Intern Med. 2012 Oct 16; 157(8):549-57.
    View in: PubMed
    Score: 0.010
  15. Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med. 1992 Jul 16; 327(3):157-62.
    View in: PubMed
    Score: 0.010
  16. Variants in DENND1A are associated with polycystic ovary syndrome in women of European ancestry. J Clin Endocrinol Metab. 2012 Jul; 97(7):E1342-7.
    View in: PubMed
    Score: 0.010
  17. Potential diagnostic utility of intermittent administration of short-acting gonadotropin-releasing hormone agonist in gonadotropin deficiency. Fertil Steril. 2010 Dec; 94(7):2697-702.
    View in: PubMed
    Score: 0.009
  18. Use of nafarelin for testing pituitary-ovarian function. J Reprod Med. 1989 Dec; 34(12 Suppl):1044-50.
    View in: PubMed
    Score: 0.008
  19. A new test of combined pituitary-testicular function using the gonadotropin-releasing hormone agonist nafarelin in the differentiation of gonadotropin deficiency from delayed puberty: pilot studies. J Clin Endocrinol Metab. 1989 Nov; 69(5):963-7.
    View in: PubMed
    Score: 0.008
  20. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med. 1989 Mar 02; 320(9):559-65.
    View in: PubMed
    Score: 0.008
  21. Asymptomatic volunteers with a polycystic ovary are a functionally distinct but heterogeneous population. J Clin Endocrinol Metab. 2009 May; 94(5):1579-86.
    View in: PubMed
    Score: 0.008
  22. Diagnosis of the polycystic ovary syndrome in adolescence: comparison of adolescent and adult hyperandrogenism. J Pediatr Endocrinol Metab. 2000; 13 Suppl 5:1285-9.
    View in: PubMed
    Score: 0.004
  23. Molecular analysis of the gonadotropin-releasing hormone receptor in patients with polycystic ovary syndrome. Fertil Steril. 1999 Aug; 72(2):360-3.
    View in: PubMed
    Score: 0.004
  24. Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab. 1994 Nov; 79(5):1328-33.
    View in: PubMed
    Score: 0.003
  25. Ovarian steroidogenic responses to gonadotropin-releasing hormone agonist testing with nafarelin in hirsute women with adrenal responses to adrenocorticotropin suggestive of 3 beta-hydroxy-delta 5-steroid dehydrogenase deficiency. J Clin Endocrinol Metab. 1993 Feb; 76(2):450-5.
    View in: PubMed
    Score: 0.003
  26. Maturation of gonadotropin and sex steroid responses to gonadotropin-releasing hormone agonist in males. J Clin Endocrinol Metab. 1993 Feb; 76(2):362-6.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.